Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Cell Therapy' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Cell Screening Tools, Stem Cells and Related Analytical Products for Drug/Cell Therapy R&D Equipment, Tools, Technologies, Opportunities & WW Market Outlook |
January 2010 | £1515 | 100 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3300 | 85 % |
|
Cell Therapy Clinical Trial Analysis |
July 2009 | £660 | 82 % |
|
Islet Transplantation and Beta, Cell Replacement therapy |
April 2007 | £145 | 81 % |
|
Stem Cell Therapy International Corporation-Financial Company Report |
March 2009 | £120 | 79 % |
|
Cell Therapy Markets |
July 2007 | £2245 | 50 % |
|
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report |
January 2010 | £985 | 41 % |
|
Rebuilding the Infarcted Heart |
November 2007 | £100 | 35 % |
|
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report |
January 2010 | £985 | 34 % |
|
Biotechnology in Australia IBISWorld Industry Report |
April 2009 | £390 | 32.5 % |
|
Acne and Its Therapy |
May 2007 | £115 | 31.15 % |
|
Commercial Insight: Top 20 Cancer Therapy Brands Sales of targeted therapies overtake cytotoxics in 2006 |
July 2007 | £5020 | 30.5 % |
|
Antibody Drug Target Atlas in Oncology |
June 2007 | £1755 | 29.5 % |
|
Stem Cells for Cardiovascular Disease 2009 Market Report |
January 2009 | £2000 | 29.4 % |
|
Understanding Stem Cell Research |
January 2009 | £395 | 28.7 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2970 | 28 % |
|
CD20 Antibodies Competitor Analysis |
January 2009 | £180 | 27.5 % |
|
PARP Inhibitors Competitor Analysis |
April 2009 | £90 | 27 % |
|
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report |
February 2008 | £985 | 26.95 % |
|
Multiple Myeloma |
October 2007 | £105 | 26.6 % |
|
CHK and KSP/Eg5 Inhibitors Competitor Analysis |
August 2009 | £155 | 26 % |
|
Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer |
May 2007 | £2780 | 25.5 % |
|
Stem Cell-Based Therapeutic Delivery Challenges & Opportunities |
December 2008 | £945 | 25.2 % |
|
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments World Market |
May 2007 | £1320 | 25 % |
|
Targeted Therapies in Oncology |
September 2007 | £105 | 25 % |
|
Financial Markets Research: ASCO Review Part IICO 2006 Annual Meeting A summary of highlights presented at the ASCO 2006 Annual Meeting |
August 2006 | £1450 | 24.85 % |
|
Clinical Cell Culture Limited Product Pipeline Analysis |
August 2008 | £495 | 24.5 % |
|
Competitor Analysis: BlyS, BAFF & APRIL Antagonists |
February 2010 | £90 | 23.5 % |
|
Competitor Analysis: PSMA & PSA Targeted Therapy |
January 2010 | £135 | 23.5 % |
|
Stem Cell Research Market Trends, Investment Trends and Pipeline Analysis |
February 2010 | £2310 | 23.45 % |
|
Prognostic and Predictive Factors in Gynecologic Cancers |
September 2007 | £55 | 22.75 % |
|
Financial Markets Research: ASCO Review Part II A summary of highlights presented at the ASCO 2006 Annual Meeting |
August 2006 | £1450 | 22.05 % |
|
Competitor Analysis: Targeted Therapy of Hepatitis C |
August 2009 | £450 | 22 % |
|
Stem Cell Markets |
June 2009 | £2245 | 21.7 % |
|
Stem Cell Therapeutics Markets |
February 2002 | £1650 | 21.7 % |
|
Stakeholder Opinions Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies |
July 2008 | £2510 | 21.7 % |
|
The Vulnerable Plaque, 2nd edition |
April 2007 | £210 | 21.35 % |
|
Opportunities in Stem Cell Research and Commercialization Technology advances, regulatory impact and key players |
April 2006 | £1495 | 21.35 % |
|
Poniard Pharmaceuticals Inc Premium Company Profile |
April 2008 | £175 | 21 % |
|
Global Cancer Focus Company Directory |
April 2007 | £1400 | 20.3 % |
|
Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products China Pharmaceutical Guidebook Series (4) (3rd edition) |
October 2009 | £495 | 20.3 % |
|
Therakos Medical Device Company Intelligence Report |
August 2009 | £145 | 20 % |
|
Emerging Diabetes Drugs Competitor Analysis |
November 2008 | £540 | 19.6 % |
|
Cancer Therapies: Technologies and Global Markets |
January 2008 | £3205 | 19.6 % |
|
Understanding Genomics and Global Health Impacts The Study of Disease at the Cellular and Molecular Level |
January 2009 | £460 | 19.6 % |
|
Bortezomib: Core Country Coverage Pipeline Selector |
Ongoing | £270 | 19.5 % |
|
Novel Mitotic Kinase Inhibitors Competitor Analysis |
May 2009 | £315 | 19.5 % |
|
Bortezomib: Extended Country Coverage Pipeline Selector |
Ongoing | £625 | 19.5 % |
|
Aripiprazole Pipeline Developer |
Ongoing | £3450 | 19.5 % |
|
Myelodysplastic Syndromes - First Approvals Spur Some Interest In A Niche Market Stakeholder Opinions |
December 2007 | £1320 | 19.25 % |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 | 19 % |
|
Lymphoma A Therapeutic & Competitive Insight |
May 2006 | £1745 | 18.9 % |
|
Global Pipeline Review & Analysis of Hematological Malignancies |
March 2007 | £2115 | 18.2 % |
|
Textbook of Interventional Cardiovascular Pharmacology |
April 2007 | £140 | 18.2 % |
|
Gene Therapy Worldwide Market Challenges & Opportunities |
November 2009 | £1980 | 18.2 % |
|
Cell/Tissue Culture Supplies A Global Market Perspective |
November 2009 | £1980 | 17.85 % |
|
Non-Hodgkin's Lymphoma - Is There Room To Emulate Rituxan's Success? Stakeholder Opinions |
December 2007 | £1320 | 17.85 % |
|
Cancer Cell Therapy Markets |
March 2008 | £2245 | 17.85 % |
|
Cellular Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £895 | 17.5 % |
|
Hematological Cancers - A Therapeutic & Competitive Insight |
October 2006 | £2645 | 16.8 % |
|
Contemporary Targeted Therapies in Rheumatology |
August 2007 | £95 | 16.8 % |
|
Regenerative Medicine Global Market Trends |
November 2009 | £1980 | 16.8 % |
|
Non-Small Cell Lung Cancer Drug Pipeline Update 2007 |
April 2007 | £1345 | 16.5 % |
|
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy Stakeholder Opinions |
December 2007 | £1320 | 16.45 % |
|
CellTran Limited Product Pipeline Analysis |
August 2008 | £495 | 16.45 % |
|
Image-Guided Radiotherapy of Lung Cancer |
August 2007 | £130 | 16.45 % |
|
Cancer-Associated Thrombosis |
August 2007 | £115 | 16.45 % |
|
Analytical Tool - Hematological Cancers |
May 2007 | £5330 | 16.45 % |
|
Biotest Diagnostics Corporation Product Pipeline Analysis |
August 2008 | £495 | 16.1 % |
|
Competitive Outlook on Non-Antibody Based Cancer Vaccines |
August 2006 | £1745 | 16.1 % |
|
Biotechnology and Biopharmaceuticals Transforming Proteins and Genes into Drugs |
July 2003 | £55.95 | 16.1 % |
|
Strategic Outlook on Protein Kinase Inhibitors in Oncology |
February 2006 | £1745 | 16.1 % |
|
Melanoma - Targeted Therapeutics |
July 2007 | £1400 | 16.1 % |
|
Stem Cell Therapies and Regenerative Medicine Current Applications and Future Possibilities |
December 2005 | £2885 | 16.1 % |
|
Immunotoxins Competitor Analysis |
July 2009 | £135 | 16 % |
|
Gene Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £1345 | 16 % |
|
U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products |
March 2006 | £1980 | 16 % |
|
Serono Prospects to 2010 Prospects to 2010 |
November 2006 | £795 | 15.5 % |
|
Apoptotic Therapeutics in Oncology - Where to Commercialize? |
November 2009 | £2195 | 15.4 % |
|
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
August 2008 | £1745 | 15.4 % |
|
Immunicon Corporation Product Pipeline Analysis |
May 2008 | £495 | 15.4 % |
|
CytoCore, Inc. Product Pipeline Analysis |
August 2008 | £495 | 15.05 % |
|
Partneringdesk deals and alliances in blood and lymphatic diseases |
April 2006 | £1250 | 15 % |
|
PI3K-Akt-mTOR Pathway Inhibitors Competitor Analysis |
July 2009 | £450 | 15 % |
|
Crohn's Disease Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1320 | 15 % |
|
RNA Interference Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £895 | 15 % |
|
Diagnostics and Therapeutics for Genetic Diseases |
April 2006 | £2885 | 14.7 % |
|
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
September 2008 | £1745 | 14.7 % |
|
Cytokine Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £895 | 14.5 % |
|
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies |
July 2007 | £945 | 14.35 % |
|
Stakeholder Opinions: Ovarian Cancer Growing importance as secondary indication for targeted therapies |
July 2006 | £1450 | 14.35 % |
|
Stakeholder Opinions: Biologics in Infectious Diseases Well Defined Target Populations Are Key to Commercial Success |
March 2008 | £1320 | 14.35 % |
|
Arthro Kinetics plc Product Pipeline Analysis |
August 2008 | £495 | 14 % |
|
Immunotherapies and Vaccines for Cancer and Infectious Diseases |
October 2008 | £2475 | 14 % |
|
Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20 year old drugs |
November 2008 | £1320 | 14 % |
|
Cardiovascular Drug Delivery Technologies, Markets and Companies |
March 2010 | £1650 | 13.65 % |
|
Renal Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 13.5 % |
|
Renal Cancer Drug Pipeline Update 2009 |
May 2007 | £1345 | 13.5 % |
|
Prostate Cancer Drug Pipeline Update 2009 |
May 2007 | £1345 | 13.5 % |
|
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2010 |
January 2010 | £1345 | 13.5 % |
|
Nanobiotechnologies Applications, Markets and Companies |
May 2009 | £2640 | 13.5 % |
|
Renal Cell Carcimona Drug Discoveries - what the future holds |
February 2010 | £1295 | 13.3 % |
|
Hematological Cancers Drug Pipeline Update 2009 |
January 2009 | £1790 | 13 % |
|
Radiation Therapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £1345 | 13 % |
|
Lymphoma Drug Pipeline Update 2009 |
January 2009 | £1345 | 13 % |
|
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2009 |
May 2007 | £1345 | 13 % |
|
Immunomodulators Therapeutic Needs, Pipelines & Prospects |
August 2007 | £1495 | 12.95 % |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1075 | 12.95 % |
|
The Future of Monoclonal Antibodies Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
December 2009 | £2310 | 12.6 % |
|
Indian Biotechnology |
January 2008 | £600 | 12.6 % |
|
Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
December 2006 | £3965 | 12.6 % |
|
Melanoma Drug Pipeline Update 2009 |
January 2009 | £1345 | 12.5 % |
|
Leukemia Drug Pipeline Update 2009 |
January 2009 | £1345 | 12.5 % |
|
Baxter International Medical Device Company Intelligence Report |
March 2009 | £295 | 12.5 % |
|
Prostate Cancer - A Therapeutic & Competitive Insight Pipeline Update 2010 |
January 2010 | £1345 | 12.5 % |
|
Colorectal Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 | 12.5 % |
|
Genomic Health, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 12.5 % |
|
Cancer Therapeutics Markets |
May 2008 | £2245 | 12.25 % |
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology |
August 2006 | £3090 | 12.25 % |
|
Bladder Cancer Drug Pipeline Update 2009 |
January 2009 | £895 | 12 % |
|
Lymphoma Drug Pipeline Update 2010 |
January 2010 | £1345 | 12 % |
|
Immunotherapy in Oncology Drug Pipeline Update 2010 |
January 2010 | £2195 | 12 % |
|
Liver Cancer Drug Pipeline Update 2009 |
January 2009 | £895 | 12 % |
|
Colorectal Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 12 % |
|
Neuroendocrine Tumors Drug Pipeline Update 2010 |
January 2010 | £895 | 12 % |
|
Cancer Therapeutics Market Insight and R&D Pipeline Analysis |
August 2008 | £2310 | 11.9 % |
|
Stakeholder Opinions: Sepsis The Critical Care Community Gains Critical Mass |
March 2008 | £1355 | 11.9 % |
|
GSK's Cervarix A Future Blockbuster of 2007 |
March 2007 | £1999 | 11.9 % |
|
Lung Cancer Therapeutics |
July 2009 | £2610 | 11.9 % |
|
Personalized Medicine: Technologies and the Global Market |
July 2009 | £3205 | 11.9 % |
|
Decoding Big Pharma's R&D Strategy in Oncology |
September 2007 | £1755 | 11.9 % |
|
World market for cancer vaccines 2007-2012 |
January 2007 | £1999 | 11.9 % |
|
Drug Delivery Technology Revolutionizing Diabetes Treatment |
September 2007 | £945 | 11.55 % |
|
Stakeholder Opinions: Acute Leukemias Persistent unmet needs confer significant commercial opportunity |
April 2006 | £1435 | 11.55 % |
|
Drug Delivery to CNS |
March 2010 | £1850 | 11.55 % |
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology |
August 2006 | £3090 | 11.55 % |
|
Cancer Vaccine Developments to 2011 |
September 2007 | £1296 | 11.55 % |
|
Drug Delivery Technology: Revolutionizing Diabetes Treatment |
September 2007 | £945 | 11.55 % |
|
Orthopedic Biomaterials, The World Market, 2nd Edition |
September 2007 | £2310 | 11.55 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1850 | 11.55 % |
|
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies |
May 2006 | £3090 | 11.55 % |
|
Orthopedic Biomaterials, The World Market 2nd Edition |
September 2007 | £2310 | 11.55 % |
|
Regenerative Medicines: Bone and Joint Applications |
October 2009 | £3205 | 11.55 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1650 | 11.55 % |
|
Lung Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Melanoma Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Leukemia - A Therapeutic & Competitive Insight |
October 2006 | £1745 | 11.5 % |
|
Breast Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Lung Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 | 11.5 % |
|
Ovarian Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 | 11.5 % |
|
Pancreatic Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 | 11.5 % |
|
Vascular Targeting and Anti-angiogenesis in Oncology Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Head and Neck Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Brain Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 | 11.5 % |
|
Hematological Cancers Drug Pipeline Update 2010 |
January 2010 | £1790 | 11.5 % |
|
Cancer Vaccines Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Leukemia Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Antibodies in Oncology Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Bladder Cancer Drug Pipeline Update 2010 |
January 2010 | £895 | 11.5 % |
|
Brain Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 11.5 % |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1745 | 11.2 % |
|
Psoriasis and Psoriatic Arthritis A Strategic Analysis of the Market in the United States |
September 2006 | £2310 | 11.2 % |
|
Drug Delivery: Principles and Applications |
May 2005 | £61.5 | 11.2 % |
|
Prostate Cancer Therapeutics A Global Market Perspective |
November 2009 | £1980 | 11.2 % |
|
U.S. Markets for Orthopedic Biomaterials 2008 |
January 2008 | £4950 | 11.2 % |
|
Inflammatory Directions Strategies for Six Diseases with Unmet Needs |
April 2008 | £745 | 11.2 % |
|
Breast Cancer Drug Pipeline Update 2009 |
January 2009 | £1345 | 11 % |
|
Bcr-Abl Kinase Inhibitors Competitor Analysis |
July 2009 | £180 | 11 % |
|
Angiogenesis in Oncology Drug Pipeline Update 2009 |
January 2009 | £1345 | 11 % |
|
Cancer Vaccines Drug Pipeline Update 2009 |
January 2009 | £1345 | 11 % |
|
Parkinson's Disease Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1320 | 11 % |
|
Peptides in Oncology Drug Pipeline Update 2010 |
January 2010 | £1345 | 11 % |
|
Pancreatic Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 11 % |
|
Apoptosis in Oncology Pipeline Update 2010 |
January 2010 | £1345 | 11 % |
|
Liver Cancer Drug Pipeline Update 2010 |
January 2010 | £895 | 11 % |
|
Monoclonal Antibodies in Asthma The choice between life and breath? |
February 2006 | £725 | 10.85 % |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £3090 | 10.85 % |
|
U.S. Markets for Orthopedic Biomaterials 2008 |
August 2008 | £4950 | 10.85 % |
|
The Global Multiple Sclerosis Market 2009-2024 |
March 2009 | £1499 | 10.85 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 10.85 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 10.5 % |
|
China Asthma Drug Market Report The Chinese Asthma Drug Drug Utilization |
May 2009 | £2970 | 10.5 % |
|
Alzheimer's Disease Biomarkers, 2009 |
January 2009 | £1499 | 10.5 % |
|
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics |
April 2008 | £2015 | 10.5 % |
|
Ovarian Cancer Drug Pipeline Update 2010 |
January 2010 | £1345 | 10.5 % |
|
R&D Pipeline News - Therapeutic Area Edition: 1-Month Subscription Periodical |
October 2008 | £90 | 10.5 % |
|
Emerging Opportunities with Cannabinoids |
September 2008 | £795 | 10.5 % |
|
Global Biotechnology Markets Trends |
November 2008 | £460 | 10.5 % |
|
Global Image Dermatology Drug Market, 2005-2012, The High-Growth Opportunities in Aesthetic Medicine |
November 2005 | £795 | 10.5 % |
|
Modern Biopharmaceuticals Design, Development and Optimization, 4 Volumes |
September 2005 | £440 | 10.15 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 10 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC |
July 2007 | £2475 | 9.8 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas |
June 2007 | £2475 | 9.8 % |
|
Organ Transplant Immunosuppressive Markets |
January 2008 | £2310 | 9.8 % |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £5020 | 9.8 % |
|
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development |
June 2004 | £895 | 9.8 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2195 | 9.8 % |
|
Emerging Markets Series: The Pharmaceutical Market of South Korea |
October 2008 | £2640 | 9.8 % |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 | 9.8 % |
|
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis |
November 2009 | £985 | 9.8 % |
|
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology |
December 2006 | £3090 | 9.8 % |
|
Market for Advanced Wound Care Technology; The |
January 2007 | £2885 | 9.8 % |
|
Top 7 Cancer Indications Therapeutic & Competitive Insights |
January 2007 | £6225 | 9.8 % |
|
Monoclonal Antibodies Report |
June 2008 | £2510 | 9.45 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £3965 | 9.45 % |
|
Breast Cancer Therapeutic And Competitive Insights |
February 2007 | £1400 | 9.45 % |
|
Ribonucleic Acid (RNA) Therapeutics Strong Potential to Address Unmet Needs in Pharma |
February 2010 | £2310 | 9.45 % |
|
Market for Bioengineered Protein Drugs; The |
January 2007 | £2885 | 9.45 % |
|
Currently Druggable in Melanoma A Drug Target Competitive Analysis |
October 2008 | £1745 | 9.45 % |
|
Multiple Myeloma Therapeutics US Market Trends & Analysis |
November 2009 | £1980 | 9.45 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2115 | 9.45 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer |
June 2007 | £2475 | 9.45 % |
|
Wound Care Management Pipeline Product Analysis and Technology Report |
December 2008 | £890 | 9.45 % |
|
Immunogenicity to Biologics Implications Of Reactions Against Biotech Drugs |
November 2007 | £1450 | 9.45 % |
|
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology |
December 2006 | £4635 | 9.1 % |
|
Pre-clinical Stage Partnering Agreements in Biopharma |
October 2008 | £1195 | 9.1 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1850 | 9.1 % |
|
Radiopharmaceuticals A US and European Market Analysis |
November 2009 | £1980 | 9.1 % |
|
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline |
May 2008 | £3965 | 9.1 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £3965 | 9.1 % |
|
ASCO 2009: Significant Developments in Context |
July 2009 | £595 | 9.1 % |
|
Blood Purification Equipment Clinical Trial Analysis |
July 2009 | £660 | 9.1 % |
|
Cordis Medical Device Company Intelligence Report |
August 2009 | £195 | 8.75 % |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4435 | 8.75 % |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £3090 | 8.75 % |
|
Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics |
June 2007 | £1495 | 8.75 % |
|
Monoclonal Antibodies Report Part I |
June 2007 | £2510 | 8.75 % |
|
Drug Delivery Technology: Revolutionizing CNS Therapies |
December 2007 | £945 | 8.75 % |
|
Instruments Clinical Trial Analysis |
July 2009 | £660 | 8.75 % |
|
Cancer Therapies Global Market Opportunities |
November 2009 | £1980 | 8.75 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2310 | 8.75 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1745 | 8.75 % |
|
Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
December 2008 | £1745 | 8.75 % |
|
R&D Pipeline News - Technology Edition: 1-Year Subscription Periodical |
October 2008 | £715 | 8.5 % |
|
R&D Pipeline News - Therapeutic Area Edition: 1-Year Subscription Periodical |
October 2008 | £715 | 8.5 % |
|
R&D Pipeline News - Technology Edition: 1-Month Subscription Periodical |
October 2008 | £90 | 8.5 % |
|
Pfizer Inc.: PharmaVitae Profile |
July 2009 | £3765 | 8.4 % |
|
Emerging Technologies in Spinal Motion Preservation |
October 2006 | £1295 | 8.4 % |
|
Angiotech Pharmaceuticals, Inc. Product Pipeline Analysis |
August 2008 | £495 | 8.4 % |
|
Pipeline Insight: Cancer Overview Increasing Diversity Offers Both High Risk And Reward |
September 2007 | £5020 | 8.4 % |
|
Biotechnological Innovations In The Pharmaceutical Industry in Poland 2009 Development forecasts for biotechnology sector for 2009-2011 |
August 2009 | £1790 | 8.4 % |
|
Pipeline Insight: Orphan Diseases in Neurology Part III: Myasthenia Gravis |
November 2008 | £3965 | 8.4 % |
|
Stakeholder Insight: Non-Small Cell Lung Cancer The need for greater product differentiation in an increasingly crowded market |
November 2006 | £5285 | 8.4 % |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 | 8.4 % |
|
India in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1650 | 8.05 % |
|
RNAi Technologies, Markets and Companies |
March 2010 | £2310 | 8.05 % |
|
Monoclonal Antibodies in Cancer Therapy 2009-2024 |
May 2009 | £1499 | 8.05 % |
|
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs |
March 2007 | £1325 | 8.05 % |
|
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics |
August 2007 | £3965 | 8.05 % |
|
Biomedical Imaging From Drug Target Discovery to Medical Diagnostics |
December 2008 | £2475 | 8.05 % |
|
Immunotherapy of Cancer |
March 2007 | £3205 | 8.05 % |
|
Diabetes Drug Discoveries What the Future Holds |
January 2007 | £1495 | 8.05 % |
|
Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis 3rd Edition |
November 2008 | £2640 | 8.05 % |
|
Beckman Coulter, Inc. Product Pipeline Analysis |
August 2008 | £495 | 8.05 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £5285 | 7.7 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £3965 | 7.7 % |
|
Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
December 2006 | £1325 | 7.7 % |
|
Cancer Personalized Medicine 2008 |
July 2008 | £2425 | 7.7 % |
|
Pharmaceutical Regulatory Affairs in the EU and US |
December 2006 | £1095 | 7.5 % |
|
DNA Diagnostics: Technologies and Global Markets |
January 2008 | £3205 | 7.35 % |
|
Orphan Drugs to 2008 Understanding regulation & market opportunity in Europe |
January 2005 | £995 | 7.35 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2310 | 7.35 % |
|
Neuroprotection Drugs, Markets and Companies |
March 2010 | £2970 | 7.35 % |
|
Therapeutics for Inflammatory Diseases Current Challenges and Future Market |
March 2006 | £2885 | 7.35 % |
|
Tumour Markers Clinical Trial Analysis |
July 2009 | £660 | 7.35 % |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 | 7.35 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £5745 | 7.35 % |
|
Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
November 2008 | £5285 | 7.35 % |
|
All Change in the Advanced Wound Care Market 2009 |
May 2009 | £795 | 7.35 % |
|
Advances in Molecular Imaging Companies and Technologies that are driving change |
February 2010 | £695 | 7 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £2970 | 7 % |
|
World Diabetes Market Analysis 2009-2023 |
February 2009 | £1499 | 7 % |
|
Glucose Monitoring Clinical Trial Analysis |
July 2009 | £660 | 7 % |
|
Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), The |
October 2009 | £2310 | 7 % |
|
Stakeholder Opinions: Systemic Lupus Erythematosus Market Set to Enter Era of Biologic Therapies |
March 2008 | £1355 | 7 % |
|
Growth Factors (Blood and Tissue) A World Report |
November 2009 | £1980 | 7 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3205 | 7 % |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 | 6.65 % |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £1320 | 6.65 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 6.65 % |
|
A Practical Guide to Biopharmaceutical Manufacturing |
January 2006 | £1095 | 6.65 % |
|
Diabetes and Diabetic Complications Major World Markets, 3rd Ed. |
March 2007 | £2640 | 6.65 % |
|
Personalized Medicine Scientific & Commercial Aspects |
March 2010 | £2640 | 6.65 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £745 | 6.65 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £3965 | 6.65 % |
|
Burger's Medicinal Chemistry and Drug Discovery 6 Volume Set |
March 2003 | £1730 | 6.65 % |
|
Infusion Devices: Technologies and Global Markets |
February 2010 | £3205 | 6.65 % |
|
Bladder Cancer Therapeutics |
February 2010 | £2610 | 6.65 % |
|
Prostate and Breast Cancer New Treatments & Developmental Progress |
March 2007 | £2115 | 6.65 % |
|
Drug-Device Combinations The Global Market |
January 2010 | £3205 | 6.3 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £5285 | 6.3 % |
|
Cardiovascular Monitoring and Diagnostic Devices Clinical Trial Analysis |
July 2009 | £660 | 6.3 % |
|
Drug Approval Trends at the FDA and EMEA Process Improvements, Heightened Scrutiny and Industry Response |
April 2008 | £1995 | 6.3 % |
|
Pediatric Health Care Products and Services |
March 2009 | £3205 | 6.3 % |
|
Pipeline Insight: HIV Extending treatment options |
September 2006 | £3965 | 6.3 % |
|
Cancer Biomarkers Enhancing diagnostic, therapeutic and developmental strategies |
May 2006 | £1450 | 6.3 % |
|
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome |
January 2009 | £1320 | 6.3 % |
|
Advanced Wound Management Clinical Trial Analysis |
July 2009 | £660 | 6.3 % |
|
Innovative Drug R&D in China |
October 2009 | £1910 | 6 % |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 | 6 % |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
April 2009 | £2245 | 5.95 % |
|
Clinical Trials Business; The |
August 2006 | £2885 | 5.95 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 5.95 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 5.95 % |
|
Genetic Test Reagents Clinical Trial Analysis |
July 2009 | £660 | 5.95 % |
|
Animal Biotechnology Technologies, Markets and Companies |
March 2010 | £1650 | 5.95 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2970 | 5.95 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 5.95 % |
|
Takeda: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 5.95 % |
|
Labeling and Linkage Agents for Immunoassays and Gene Probes |
April 2006 | £2885 | 5.95 % |
|
Small Molecule Kinase Inhibitors |
July 2009 | £2610 | 5.95 % |
|
Global Ophthalmic Market Analysis & Forecasts to 2012 |
April 2007 | £1499 | 5.95 % |
|
Approaches to Reducing Phase II Attrition |
May 2009 | £2475 | 5.6 % |
|
United Kingdom in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1650 | 5.6 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £3965 | 5.6 % |
|
Drug Delivery Technologies: Players, products & prospects to 2015 |
November 2007 | £1795 | 5.6 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 5.6 % |
|
Advanced Orthopedic Technologies, Implants and Regenerative Products |
May 2007 | £3205 | 5.6 % |
|
Alzheimer's disease |
March 2010 | £2115 | 5.6 % |
|
Osteoporosis & Bone Metabolism Disorders Market 2008-2023 |
August 2008 | £1499 | 5.6 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 5.6 % |
|
Smith & Nephew Medical Device Company Intelligence Report |
April 2007 | £395 | 5.6 % |
|
Interventional Cardiology Clinical Trial Analysis |
July 2009 | £660 | 5.6 % |
|
Biomarkers Technologies, Markets and Companies |
March 2010 | £2970 | 5.25 % |
|
Cordis Corporation Product Pipeline Analysis |
August 2008 | £495 | 5.25 % |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2245 | 5.25 % |
|
The World Antibacterial Treatments Market 2010-2024 |
December 2009 | £1499 | 5.25 % |
|
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 |
February 2007 | £1499 | 5.25 % |
|
Antibiotic Resistance and Antibiotic Technologies: Global Markets |
November 2009 | £3205 | 5.25 % |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 | 5.25 % |
|
Global Antivirals Market Analysis & Forecasts 2008-2023 |
September 2008 | £1499 | 4.9 % |
|
Pharmacogenomics: New Technologies In the Development of Personalized Therapies |
August 2005 | £2885 | 4.9 % |
|
Orthobiologics Clinical Trial Analysis |
July 2009 | £660 | 4.9 % |
|
Innovations in Cardiovascular Disease Management Latest surgical procedures, drugs and medical devices |
September 2007 | £1495 | 4.9 % |
|
Medical Device Coatings |
November 2008 | £3205 | 4.55 % |
|
Spinal Orthopaedics: A bright future for new technologies? |
September 2008 | £1295 | 4.55 % |
|
Global Protein Therapeutics Market, The Market Dynamics and Pipeline Analysis |
December 2006 | £1980 | 4.55 % |
|
Coronary Stents Global Market Trends |
November 2009 | £1980 | 4.2 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
March 2010 | £3300 | 4.2 % |
|
Implant-Based Dental Reconstruction World Dental Implant and Bone Graft Market, 3rd Edition |
September 2009 | £2310 | 3.85 % |
|
Asian Medical Device Markets |
May 2007 | £2640 | 3.85 % |
|
RFID Opportunities in Healthcare in the U.S. |
June 2007 | £2640 | 3.85 % |
|
Anti-Infectives |
February 2010 | £2610 | 3.85 % |
|
Bone Grafts A US Market Analysis |
November 2009 | £1980 | 3.85 % |
|
U.S. Market for Home Care Products, 5th Edition |
May 2007 | £2640 | 3.85 % |
|
Blood The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products |
September 2006 | £2575 | 3.85 % |
|
United States Drug Delivery Devices Medical Equipment Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies |
April 2008 | £1980 | 3.85 % |
|
Generic League Market Analysis and Forecasts, 2007-2012, 2017 & 2022 |
February 2008 | £1999 | 3.5 % |
|
Global Medical Markets for Nanoscale Materials and Devices |
January 2008 | £3205 | 3.15 % |
|
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1980 | 3.15 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 3.15 % |
|
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1980 | 2.8 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2009 / 2010 |
June 2009 | £280 | 2.8 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £280 | 2.8 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2245 | 2.8 % |
|
Orthopedic Instrumentation A Global Market Perspective |
November 2009 | £2280 | 2.8 % |
|
World Generic Market Report 2009 |
January 2009 | £595 | 2.45 % |
